Details of the Drug Combination

General Information of Drug Combination (ID: DC69OAG)

• Drug Combination Name: JZL195 + Methylergonovine
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• Component Drugs:
  JZL195 (DMEOCKZ): Small molecular drug
  Methylergonovine (DMBEX4O): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: KBM-7
  Zero Interaction Potency (ZIP) Score: 8.42
  Bliss Independence Score: 8.42
  Loewe Additivity Score: 22.85
  LHighest Single Agent (HSA) Score: 22.86

Molecular Interaction Atlas of This Drug Combination

Indication(s) of JZL195

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[2]

JZL195 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Acyloxyacyl hydrolase (neutrophil)	TT2EJXQ	AOAH_HUMAN	Inhibitor	[2]

Indication(s) of Methylergonovine

Disease Entry	ICD 11	Status	REF
Spontaneous abortion	JA00.0	Approved	[3]

Methylergonovine Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Dopamine D1 receptor (D1R)	TTZFYLI	DRD1_HUMAN	Antagonist	[4]

Methylergonovine Interacts with 1 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[5]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity. Nat Chem Biol. 2014 Aug;10(8):656-63.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Reinforcement in an in vitro analog of appetitive classical conditioning of feeding behavior in Aplysia: blockade by a dopamine antagonist. Learn Mem. 2005 May-Jun;12(3):216-20.
• [5] Modulation of cytochrome P450 metabolism by ergonovine and dihydroergotamine. Vet Hum Toxicol. 2003 Feb;45(1):6-9.